NeuClone Makes Progress On Ustekinumab
Reports Positive Phase I Results; Phase III Trial To Begin In 2021
Executive Summary
Australia’s NeuClone expects to be among the first biosimilar market entrants to challenge Stelara, with the firm’s NeuLara ustekinumab rival reporting positive Phase I data as the company prepares to move ahead with Phase III trials next year.